Presentation TCT 2013 No: They Are Expensive, Entail Risk, and There Is No Evidence of Benefit! Presenter: Holger Thiele October 31, 2013 REGISTER for free or LOG IN to view this content ACS/AMI Presentation TCT 2013 Up Next Presentation TCT 2013 TCT-45. Use of drug-eluting stent (DES) with bioresorbable polymer in patients with ST-segment elevation myocardial infarction (STEMI) - Mid- and long-term clinical outcomes Presenter: Andres I?iguez October 29, 2013 More slides + Presentation TCT 2013 How Strong Is the Clinical Data for Pre- and Postconditioning? Presenter: Thomas Engstr?m October 31, 2013 Presentation TCT 2013 Keynote Address: FDA-CDRH in the Next Decade – A Vision for Change Presenter: Christy Foreman October 30, 2013 We Recommend
Presentation TCT 2013 TCT-45. Use of drug-eluting stent (DES) with bioresorbable polymer in patients with ST-segment elevation myocardial infarction (STEMI) - Mid- and long-term clinical outcomes Presenter: Andres I?iguez October 29, 2013
Presentation TCT 2013 How Strong Is the Clinical Data for Pre- and Postconditioning? Presenter: Thomas Engstr?m October 31, 2013
Presentation TCT 2013 Keynote Address: FDA-CDRH in the Next Decade – A Vision for Change Presenter: Christy Foreman October 30, 2013